vitarka therapeutics ltd
vitarka therapeutics ltd Company Information
Company Number
13291464
Next Accounts
Sep 2025
Industry
Research and experimental development on biotechnology
Shareholders
vineeta tripathi
discovery park ventures
View AllGroup Structure
View All
Contact
Registered Address
innovation house innovation way, discovery park, sandwich, CT13 9FF
Website
-vitarka therapeutics ltd Estimated Valuation
Pomanda estimates the enterprise value of VITARKA THERAPEUTICS LTD at £1.6m based on a Turnover of £1.1m and 1.51x industry multiple (adjusted for size and gross margin).
vitarka therapeutics ltd Estimated Valuation
Pomanda estimates the enterprise value of VITARKA THERAPEUTICS LTD at £0 based on an EBITDA of £-440.3k and a 5.4x industry multiple (adjusted for size and gross margin).
vitarka therapeutics ltd Estimated Valuation
Pomanda estimates the enterprise value of VITARKA THERAPEUTICS LTD at £632.3k based on Net Assets of £344.4k and 1.84x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Vitarka Therapeutics Ltd Overview
Vitarka Therapeutics Ltd is a live company located in sandwich, CT13 9FF with a Companies House number of 13291464. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in March 2021, it's largest shareholder is vineeta tripathi with a 75.6% stake. Vitarka Therapeutics Ltd is a startup, small sized company, Pomanda has estimated its turnover at £1.1m with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Vitarka Therapeutics Ltd Health Check
Pomanda's financial health check has awarded Vitarka Therapeutics Ltd a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 3 areas for improvement. Company Health Check FAQs
2 Strong
3 Regular
3 Weak
Size
annual sales of £1.1m, make it smaller than the average company (£4.7m)
- Vitarka Therapeutics Ltd
£4.7m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Vitarka Therapeutics Ltd
- - Industry AVG
Production
with a gross margin of 54.3%, this company has a comparable cost of product (54.3%)
- Vitarka Therapeutics Ltd
54.3% - Industry AVG
Profitability
an operating margin of -41.8% make it less profitable than the average company (-5.5%)
- Vitarka Therapeutics Ltd
-5.5% - Industry AVG
Employees
with 8 employees, this is below the industry average (54)
8 - Vitarka Therapeutics Ltd
54 - Industry AVG
Pay Structure
on an average salary of £84.3k, the company has an equivalent pay structure (£84.3k)
- Vitarka Therapeutics Ltd
£84.3k - Industry AVG
Efficiency
resulting in sales per employee of £131.7k, this is equally as efficient (£131.7k)
- Vitarka Therapeutics Ltd
£131.7k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Vitarka Therapeutics Ltd
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Vitarka Therapeutics Ltd
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Vitarka Therapeutics Ltd
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 599 weeks, this is more cash available to meet short term requirements (30 weeks)
599 weeks - Vitarka Therapeutics Ltd
30 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 8.3%, this is a lower level of debt than the average (51.9%)
8.3% - Vitarka Therapeutics Ltd
51.9% - Industry AVG
VITARKA THERAPEUTICS LTD financials
Vitarka Therapeutics Ltd's latest turnover from December 2023 is estimated at £1.1 million and the company has net assets of £344.4 thousand. According to their latest financial statements, Vitarka Therapeutics Ltd has 8 employees and maintains cash reserves of £357.2 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Mar 2022 | |
|---|---|---|---|
| Turnover | |||
| Other Income Or Grants | |||
| Cost Of Sales | |||
| Gross Profit | |||
| Admin Expenses | |||
| Operating Profit | |||
| Interest Payable | |||
| Interest Receivable | |||
| Pre-Tax Profit | |||
| Tax | |||
| Profit After Tax | |||
| Dividends Paid | |||
| Retained Profit | |||
| Employee Costs | |||
| Number Of Employees | 8 | 2 | 1 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Mar 2022 | |
|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 |
| Misc Debtors | 18,235 | 7,892 | 0 |
| Cash | 357,175 | 129,392 | 100 |
| misc current assets | 0 | 0 | 0 |
| total current assets | 375,410 | 137,284 | 100 |
| total assets | 375,410 | 137,284 | 100 |
| Bank overdraft | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 |
| other current liabilities | 31,000 | 1,000 | 10,350 |
| total current liabilities | 31,000 | 1,000 | 10,350 |
| loans | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 |
| total liabilities | 31,000 | 1,000 | 10,350 |
| net assets | 344,410 | 136,284 | -10,250 |
| total shareholders funds | 344,410 | 136,284 | -10,250 |
| Dec 2023 | Dec 2022 | Mar 2022 | |
|---|---|---|---|
| Operating Activities | |||
| Operating Profit | |||
| Depreciation | 0 | 0 | 0 |
| Amortisation | 0 | 0 | 0 |
| Tax | |||
| Stock | 0 | 0 | 0 |
| Debtors | 10,343 | 7,892 | 0 |
| Creditors | 0 | 0 | 0 |
| Accruals and Deferred Income | 30,000 | 1,000 | 10,350 |
| Deferred Taxes & Provisions | 0 | 0 | 0 |
| Cash flow from operations | |||
| Investing Activities | |||
| capital expenditure | |||
| Change in Investments | 0 | 0 | 0 |
| cash flow from investments | |||
| Financing Activities | |||
| Bank loans | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 |
| share issue | |||
| interest | |||
| cash flow from financing | |||
| cash and cash equivalents | |||
| cash | 227,783 | 129,392 | 100 |
| overdraft | 0 | 0 | 0 |
| change in cash | 227,783 | 129,392 | 100 |
vitarka therapeutics ltd Credit Report and Business Information
Vitarka Therapeutics Ltd Competitor Analysis
Perform a competitor analysis for vitarka therapeutics ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in CT13 area or any other competitors across 12 key performance metrics.
vitarka therapeutics ltd Ownership
VITARKA THERAPEUTICS LTD group structure
Vitarka Therapeutics Ltd has no subsidiary companies.
Ultimate parent company
VITARKA THERAPEUTICS LTD
13291464
vitarka therapeutics ltd directors
Vitarka Therapeutics Ltd currently has 2 directors. The longest serving directors include Dr Vineeta Tripathi (Mar 2021) and Mr Mayer Schreiber (Apr 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Vineeta Tripathi | England | 44 years | Mar 2021 | - | Director |
| Mr Mayer Schreiber | England | 31 years | Apr 2022 | - | Director |
P&L
December 2023turnover
1.1m
+287%
operating profit
-440.3k
0%
gross margin
54.3%
+2.43%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
344.4k
+1.53%
total assets
375.4k
+1.73%
cash
357.2k
+1.76%
net assets
Total assets minus all liabilities
Similar Companies
vitarka therapeutics ltd company details
company number
13291464
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
March 2021
age
4
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
December 2023
previous names
N/A
accountant
KRESTON REEVES LLP
auditor
-
address
innovation house innovation way, discovery park, sandwich, CT13 9FF
Bank
-
Legal Advisor
-
vitarka therapeutics ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to vitarka therapeutics ltd.
vitarka therapeutics ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for VITARKA THERAPEUTICS LTD. This can take several minutes, an email will notify you when this has completed.
vitarka therapeutics ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
